{"id":32510,"date":"2025-06-19T20:42:29","date_gmt":"2025-06-19T15:12:29","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32510"},"modified":"2025-06-19T20:42:43","modified_gmt":"2025-06-19T15:12:43","slug":"medtech-news-for-presidio-medical-creo-medical-penumbra","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra","title":{"rendered":"Presidio Medical\u2122 Gains IDE Nod for ULF\u2122 Study, Names Dimas Jim\u00e9nez CFO; Creo Medical Gains FDA Nod for SpydrBlade\u2122 Flex, Paving Way for U.S. Launch; Penumbra Completes Patient Enrollment in Pivotal STORM-PE RCT; Adona Medical Completes Enrollment in First-in-Human Trial of Novel Interatrial Shunt for Heart Failure; Johnson &amp; Johnson Launches TECNIS Odyssey Intraocular Lens in Europe, Middle East, and Canada for Enhanced Cataract Care; Philips Sets New Benchmark in POCUS Technology with Flash 5100 Launch"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69dec0e117c24\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69dec0e117c24\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\/#Presidio_Medical%E2%84%A2_Received_IDE_Approval_for_Ultra_Low_Frequency_ULF%E2%84%A2_Neuromodulation_Clinical_Study_and_Appoints_Dimas_Jimenez_as_Chief_Financial_Officer\" >Presidio Medical\u2122 Received IDE Approval for Ultra Low Frequency (ULF\u2122) Neuromodulation Clinical Study and Appoints Dimas Jim\u00e9nez as Chief Financial Officer&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\/#Creo_Medical_Secured_FDA_Clearance_for_SpydrBlade%E2%84%A2_Flex_Advancing_US_Market_Launch\" >Creo Medical Secured FDA Clearance for SpydrBlade\u2122 Flex, Advancing U.S. Market Launch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\/#Penumbra_Inc_Announced_Completion_of_Enrollment_for_Landmark_STORM-PE_Randomized_Controlled_Trial\" >Penumbra, Inc. Announced Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\/#Adona_Medical_Completed_Enrollment_in_First-in-human_Trial_for_Novel_Interatrial_Shunt_for_Patients_With_Heart_Failure\" >Adona Medical Completed Enrollment in First-in-human Trial for Novel Interatrial Shunt for Patients With Heart Failure&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\/#Johnson_and_Johnson_Introduced_TECNIS_Odyssey_Next-Generation_Intraocular_Lens_Across_Europe_the_Middle_East_and_Canada_to_Provide_Cataract_Patients_with_Clear_Vision_at_All_Distances_and_Lighting_Conditions\" >Johnson and Johnson Introduced TECNIS Odyssey Next-Generation Intraocular Lens Across Europe, the Middle East, and Canada to Provide Cataract Patients with Clear Vision at All Distances and Lighting Conditions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\/#Philips_Breaks_New_Ground_in_Point-of-Care_Ultrasound_with_Launch_of_Flash_5100_POC\" >Philips Breaks New Ground in Point-of-Care Ultrasound with Launch of Flash 5100 POC&nbsp;&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-presidio-medical-received-ide-approval-for-ultra-low-frequency-ulf-neuromodulation-clinical-study-and-appoints-dimas-jimenez-as-chief-financial-officer-nbsp\"><span class=\"ez-toc-section\" id=\"Presidio_Medical%E2%84%A2_Received_IDE_Approval_for_Ultra_Low_Frequency_ULF%E2%84%A2_Neuromodulation_Clinical_Study_and_Appoints_Dimas_Jimenez_as_Chief_Financial_Officer\"><\/span><strong>Presidio Medical\u2122 Received IDE Approval for Ultra Low Frequency (ULF\u2122) Neuromodulation Clinical Study and Appoints Dimas Jim\u00e9nez as Chief Financial Officer&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On June 12, 2025, San Mateo, California\u2013Presidio Medical, Inc., a global clinical-stage medical device company, received Investigational New Drug (IDE) approval from the U.S. FDA to initiate its global, pivotal randomized controlled trial, the FULFILL Study, in both the United States and Australia. The study will evaluate the company\u2019s proprietary Ultra Low Frequency (ULF\u2122) neuromodulation platform, which delivers therapy through leads implanted in the epidural space, commonly referred to as Spinal Cord Stimulation (SCS).<\/p>\n\n\n\n<p>Presidio Medical is focused on advancing patient-centered technologies, specifically a novel approach to treating chronic nociceptive low back pain. The ULF neuromodulation platform is engineered to alleviate localized pain by diminishing neuronal activity, potentially offering sustained relief for patients who currently lack effective treatment options. As there are no approved SCS therapies for nociceptive back pain, this represents a significant unmet need in a market estimated at $20 billion.<\/p>\n\n\n\n<p>Additionally, the company is pleased to welcome Dimas Jim\u00e9nez as its new Chief Financial Officer (CFO). Mr. Jim\u00e9nez brings more than 40 years of financial expertise, with experience ranging from Wall Street to leadership roles in both established and emerging life science companies. In his new role, he will focus on strengthening Presidio\u2019s financial infrastructure, supporting the commercialization of the ULF neuromodulation system, and enhancing engagement with current and prospective investors.<\/p>\n\n\n\n<p><em>\u201cIDE approval from the FDA represents a significant milestone for Presidio and enables the study of ultra low frequency modulation of the nervous system.&nbsp; The results from our first-in-human clinical trial in Australia, which were presented by Dr. Marc Russo at NANS earlier this year, were very encouraging.&nbsp; We are excited to now begin a more robust trial, which we believe will demonstrate the safety and efficacy of our ULF platform,\u201d said Michael Onuscheck, Presidio Medical\u2019s Chief Executive Officer.<\/em><\/p>\n\n\n\n<p><em>\u201cWe are extremely pleased to welcome Dimas to the Presidio team.&nbsp; The breadth and depth of his experience within the life science industry and his expertise in working with pre-commercialization start-up organizations is invaluable as we continue to grow and evolve as a company,\u201d said Onuscheck.<\/em><\/p>\n\n\n\n<p><em>\u201cPresidio\u2019s ULF platform has the potential to greatly improve the lives of patients who suffer from debilitating chronic back pain.&nbsp; I\u2019ve spent a significant amount of my career working with companies whose goal is to disrupt the status quo.&nbsp; I couldn\u2019t be more excited to be a part of this mission-driven and patient-centric organization,\u201d said Jim\u00e9nez.<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/neuromodulation-devices-market\"><strong>Neuromodulation Devices Market Report<\/strong><\/a>\u201d, the neuromodulation devices market was valued at&nbsp;<strong>USD 5.71 billion<\/strong>&nbsp;in&nbsp;2023, growing at a&nbsp;<strong>CAGR&nbsp;of&nbsp;8.95%<\/strong>&nbsp;during the forecast period from&nbsp;2024 to 2030&nbsp;to reach<strong>&nbsp;USD 9.56 billion<\/strong>&nbsp;by&nbsp;2030. The demand for neuromodulation devices is primarily driven by the growing prevalence of neurological disorders and the increasing number of patients suffering from chronic pain. Additionally, increasing research and development activities, along with collaborations among key players, are significantly contributing to market growth. The rising aging population further compounds this demand, as older adults are more susceptible to neurological conditions and chronic pain. These factors collectively position the neuromodulation devices market for positive growth during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-creo-medical-secured-fda-clearance-for-spydrblade-flex-advancing-u-s-market-launch\"><span class=\"ez-toc-section\" id=\"Creo_Medical_Secured_FDA_Clearance_for_SpydrBlade%E2%84%A2_Flex_Advancing_US_Market_Launch\"><\/span><strong>Creo Medical Secured FDA Clearance for SpydrBlade\u2122 Flex, Advancing U.S. Market Launch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On June 11, 2025, Creo Medical announced that the U.S. Food and Drug Administration (FDA) granted clearance for our SpydrBlade\u2122 Flex device, a major achievement for Creo, completing FDA approvals across our full portfolio of advanced energy gastrointestinal (GI) products.<\/p>\n\n\n\n<p>SpydrBlade\u2122 Flex is an innovative, multi-functional endoscopic tool that delivers both cutting and coagulation capabilities\u2014features traditionally limited to laparoscopic surgery through a flexible endoscope. Designed to support a wide range of therapeutic endoscopy procedures, the device offers unmatched precision, adaptability, and versatility, equipping clinicians with a powerful solution to streamline complex interventions and drive broader clinical adoption.<\/p>\n\n\n\n<p>Since its successful commercial debut in Europe in March 2025, SpydrBlade\u2122 Flex has already proven its clinical utility in procedures such as Zenker\u2019s Peroral Endoscopic Myotomy (Z-POEM), Colonic Endoscopic Submucosal Dissection (ESD), Oesophageal ESD, POEM, and F-POEM<\/p>\n\n\n\n<p>With FDA clearance now in place, Creo is set to begin commercial rollout in the U.S., supported by its robust direct sales team and a well-established network of leading clinical experts.<\/p>\n\n\n\n<p><em>Craig Gulliford, Chief Executive Officer of Creo, said: \u201cThis is a proud and pivotal moment for Creo. FDA clearance for SpydrBlade\u2122 Flex confirms the strength and novelty of our GI product portfolio. The device has overcome significant design challenges, with unique intellectual property that sets it apart in the market.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cProfessor Robert Hawes, MD, once described SpydrBlade\u2122 Flex as \u2018the harmonic scalpel at the end of a flexible scope,\u2019 which perfectly encapsulates our goal: bringing operating room capability into flexible endoscopy.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cWith a clear path to reimbursement and a ready-to-deploy sales infrastructure, we\u2019re excited about bringing SpydrBlade\u2122 Flex to clinicians and patients across the United States.\u201d<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/endoscopes-market\"><strong>Endoscopes Market Report<\/strong><\/a>\u201d, the endoscopes market was valued at&nbsp;<strong>USD 12.95 billion<\/strong>&nbsp;in 2023, growing at a&nbsp;<strong>CAGR of 6.05%<\/strong>&nbsp;during the forecast period from 2024 to 2030 to reach<strong>&nbsp;USD 18.32 billion<\/strong>&nbsp;by 2030. The increase in demand for endoscopes is primarily attributed to the increasing prevalence of chronic disease which require the use of endoscopes for diagnosis, such as some gastrointestinal diseases like irritable bowel syndrome (IBD), gastroesophageal reflux disease (GERD), peptic ulcer disease, and crohn&#8217;s disease, increase in number of geriatric population who are more prone to chronic ailments, increasing awareness and demand of minimally invasive surgeries and no blood loss surgery, and rise in technological advancements in endoscopes like image magnification, high-definition optical systems and digital imaging are anticipated to bolster the market, thereby contributing to the growth of the endoscopes market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-penumbra-inc-announced-completion-of-enrollment-for-landmark-storm-pe-randomized-controlled-trial-nbsp\"><span class=\"ez-toc-section\" id=\"Penumbra_Inc_Announced_Completion_of_Enrollment_for_Landmark_STORM-PE_Randomized_Controlled_Trial\"><\/span><strong>Penumbra, Inc. Announced Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On June 16, 2025, Penumbra, Inc., a global leader in thrombectomy, announced the completion of patient enrollment in the STORM-PE clinical trial, a pivotal, prospective, multi-center randomized controlled study. The trial enrolled 100 patients to compare the effectiveness of computer-assisted vacuum thrombectomy (CAVT) using Penumbra\u2019s Lightning Flash\u2122 system combined with anticoagulation therapy, against anticoagulation therapy alone, for treating acute intermediate-high risk pulmonary embolism (PE).<\/p>\n\n\n\n<p>Conducted in collaboration with The PERT Consortium\u00ae, a multidisciplinary organization focused on enhancing PE patient care, the study aims to generate high-quality evidence on the benefits of CAVT in improving right heart function and clinical outcomes in this critically ill population.<\/p>\n\n\n\n<p>In the United States, approximately 900,000 cases of symptomatic PE are reported each year, with 10\u201330% of affected individuals dying within one month of diagnosis, underscoring the severity of the condition.<\/p>\n\n\n\n<p>Penumbra\u2019s Lightning Flash system represents the most advanced mechanical thrombectomy technology available for treating venous and pulmonary thrombi. Incorporating the company\u2019s Lightning CAVT platform, it features state-of-the-art dual clot detection algorithms that utilize both pressure and flow sensing to distinguish between clot and blood flow. The system includes a MaxID hypotube-based catheter, offering a large inner diameter while maintaining a slim, flexible profile with a soft, atraumatic tip\u2014designed to ensure efficient, safe, and streamlined clot removal, even within the body\u2019s complex vascular anatomy.<\/p>\n\n\n\n<p><em>\u201cThis is an important milestone that underscores Penumbra\u2019s commitment to transforming care for patients with pulmonary embolism,\u201d said James F. Benenati, MD, FSIR, chief medical officer at Penumbra. \u201cThe trial successfully randomized patients well ahead of schedule thanks to the dedication of our clinical partners and the tireless efforts of our internal teams.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cPulmonary embolism remains a leading cause of cardiovascular morbidity and mortality, yet treatment strategies for intermediate-high risk patients are not well defined,\u201d said Rachel Rosovsky, MD, MPH, co-global principal investigator of STORM-PE and hematologist at the Massachusetts General Hospital. \u201cThe results of this trial will provide level 1 clinical evidence aimed at informing treatment guidelines and patient care.\u201d<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/thrombectomy-devices-market\"><strong>Thrombectomy Devices Market Report<\/strong><\/a>\u201d, the thrombectomy devices market&nbsp;is poised for significant growth, projected to achieve a remarkable <strong>CAGR of 5.24%<\/strong>&nbsp;during the forecast period from 2024 to 2030. The demand for thrombectomy devices is being boosted by the increasing prevalence of lifestyle disorders such as low blood pressure, diabetes, obesity, age, and others. Further, the increasing prevalence of venous thromboembolism, cardiovascular diseases, cancer, and neurological diseases, such as&nbsp;ischemic stroke, hemorrhagic stroke, and peripheral diseases, among other,s will lead to the formation of blood clots, thereby leading to the increased demand for thrombectomy devices.<\/p>\n\n\n\n<p>In addition, the increasing demand for minimally invasive approaches for treatment, lack of physical activity, rising adoption of smoking, rising device launches and approvals, surging innovations in product development, and shifting key players&#8217; focus towards the development of technologically advanced product and initiatives to increase awareness regarding neurovascular diseases and their prevention among others are thereby contributing to the overall growth of the thrombectomy devices market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-adona-medical-completed-enrollment-in-first-in-human-trial-for-novel-interatrial-shunt-for-patients-with-heart-failure-nbsp\"><span class=\"ez-toc-section\" id=\"Adona_Medical_Completed_Enrollment_in_First-in-human_Trial_for_Novel_Interatrial_Shunt_for_Patients_With_Heart_Failure\"><\/span><strong>Adona Medical Completed Enrollment in First-in-human Trial for Novel Interatrial Shunt for Patients With Heart Failure&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On June 17, 2025, Adona Medical, a portfolio company of Shifamed, announced the successful completion of enrollment in its ATHENS-HF first-in-human clinical study. The company is developing one of the world\u2019s first cardiovascular implants that combines both therapeutic and diagnostic capabilities. In this study, its chronically adjustable interatrial shunt, integrated with bi-atrial pressure monitoring, was implanted in 10 heart failure patients, achieving a 100% procedural success rate. Each patient underwent successful adjustment of the shunt diameter, both increasing and decreasing from the original setting, with measurable effects observed based on the size changes.<\/p>\n\n\n\n<p>The ATHENS-HF study included patients with both preserved and reduced ejection fraction heart failure. Most participants have now reached the 90-day follow-up milestone and, as planned, underwent additional procedures to modify the shunt size months after the initial implantation. To date, there have been no major procedural complications or site-reported major adverse cardiovascular and neurovascular events (MACNE). Adona plans to present the primary endpoint results from the study later this year.<\/p>\n\n\n\n<p>The company\u2019s device incorporates a uniquely adjustable flow channel, enabling more personalized treatment than traditional shunt technologies with fixed geometries. Additionally, the device includes embedded sensors that automatically collect pressure data from both atria several times daily without requiring any action from the patient. This continuous monitoring offers clinicians a more comprehensive view of a patient&#8217;s hemodynamic condition and has the potential to enhance shunt therapy by supporting more precise and proactive treatment decisions.<\/p>\n\n\n\n<p><em>\u201cA \u2018one-size-fits-all\u2019 technology may not be an optimal approach for all patients because heart failure is a diverse and evolving condition. The ideal shunting solution would enable adaptive flow rates and provide hemodynamic feedback so that the shunt device could be adjusted to optimize therapy based on the patient\u2019s needs, similar to calibrating for optimal medical therapy,\u201d shared Gregg W. Stone, MD, FACC, MSCAI, Mount Sinai Heart Health System and Co-Principal Investigator for the ATHENS-HF study. \u201cThe Adona interatrial shunt is designed to allow for tailored hemodynamic modulation in response to feedback from the integrated pressure sensors and the patient\u2019s changing clinical status, offering promise to a broad patient population.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cDuring the initial cases, I have seen firsthand that the Adona shunt can be safely and reliably deployed, and that the bi-atrial sensors provide important insights into the hemodynamic condition of the patient and the immediate impact of the shunting therapy,\u201d said Gagan Singh, MD, MS, Clinical Cardiovascular Research Unit Director, University of California Davis Health, and Clinical Advisor and Proctor for ATHENS-HF. \u201cAdditionally, the early clinical experience preliminarily indicates the shunt diameter can be adjusted smaller or larger post-implantation, allowing for treatment tailored to patient-specific needs.\u201d<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/tissue-heart-valves-cardiovascular-prosthetic-devices-market\"><strong>Tissue Heart Valves Market Report<\/strong><\/a>,&#8221; the tissue heart valves market is estimated to grow at a <strong>CAGR of 7.56%<\/strong> during the forecast period from 2024 to 2030. The demand for tissue heart valves is primarily witnessing growth on account of the high prevalence of heart valve diseases such as aortic valve degeneration and\u00a0aortic stenosis, the increase in demand for minimally invasive procedures, technological advancements of the tissue heart valves, and the longer life expectancy of the geriatric population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-johnson-and-johnson-introduced-tecnis-odyssey-next-generation-intraocular-lens-across-europe-the-middle-east-and-canada-to-provide-cataract-patients-with-clear-vision-at-all-distances-and-lighting-conditions\"><span class=\"ez-toc-section\" id=\"Johnson_and_Johnson_Introduced_TECNIS_Odyssey_Next-Generation_Intraocular_Lens_Across_Europe_the_Middle_East_and_Canada_to_Provide_Cataract_Patients_with_Clear_Vision_at_All_Distances_and_Lighting_Conditions\"><\/span><strong>Johnson and Johnson Introduced TECNIS Odyssey Next-Generation Intraocular Lens Across Europe, the Middle East, and Canada to Provide Cataract Patients with Clear Vision at All Distances and Lighting Conditions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On June 17, 2025, Johnson &amp; Johnson, a global leader in eye health, announced that it had expanded its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the rollout of the TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The new full visual range IOL offered high-quality and continuous vision with an unmatched range. It allowed patients to see clearly from far to near and at intermediate distances, significantly reducing their dependence on glasses. Built on the industry-leading TECNIS platform, which combined advanced optics and proprietary materials, the TECNIS Odyssey IOL delivered consistently clear, high-contrast vision.<\/p>\n\n\n\n<p><em>\u201cTECNIS Odyssey IOL is the fastest growing PC-IOL in the United States, and we are excited to be making it available to more patients around the world. It addresses a significant unmet need for cataract patients seeking greater spectacle independence. Now, together with TECNIS PureSee, TECNIS Odyssey IOL elevates the strength and depth of our global IOL portfolio, meeting the diverse needs of today\u2019s aging population,\u201d said Peter Menziuso, Company Group Chairman, Vision, Johnson &amp; Johnson.<\/em><\/p>\n\n\n\n<p><em>\u201cFrom my early experience, what sets the TECNIS Odyssey IOL apart, is its ability to deliver consistent visual outcomes across a wide range of patients, due to its advanced design with higher tolerance to residual refractive error,\u201d said Professor Beatrice Cochener-Lamard, Head of the Ophthalmology Department at Brest University Hospital in France.<\/em><\/p>\n\n\n\n<p>Johnson &amp; Johnson launched the TECNIS Odyssey IOL as its latest innovation for enhanced visual freedom, offering clear vision at all distances near, intermediate, and far with minimal reliance on glasses. Its unique diffractive surface provided continuous vision and reduced night-time disturbances like halos and glare. Clinical results showed high patient satisfaction: 94% were pleased with overall vision, 96% with smartphone reading, and 97% with distance vision. The IOL was made available in Europe, the Middle East, Canada, the U.S., Puerto Rico, and Japan. The company also expanded its TECNIS portfolio to include TECNIS PureSee IOL in APAC and Latin America, though it had not received PMA approval in the U.S.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/intraocular-lens-market\"><strong>Intraocular Lens Market Report<\/strong><\/a>\u201d, the global intraocular lens market was valued at <strong>USD 4,648.96 million<\/strong> in 2024, growing at a <strong>CAGR of 6.12%<\/strong> during the forecast period from 2025 to 2032 to reach <strong>USD 7,414.66 million <\/strong>by 2032. The intraocular lens market is being significantly boosted by the growing cases of eye-related disorders such as cataracts, presbyopia, and astigmatism, which are increasing the demand for corrective surgical interventions. This rising disease burden is complemented by improved awareness and accessibility to eye care services, especially in developing regions, enabling more patients to seek treatment. Additionally, ongoing technological advancements in lens materials and designs, such as the development of multifocal and extended depth-of-focus lenses, are enhancing visual outcomes and patient satisfaction. Furthermore, increased product development activities by key market players are leading to the introduction of innovative and customized IOL solutions, collectively accelerating the growth of the global intraocular lens market during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-philips-breaks-new-ground-in-point-of-care-ultrasound-with-launch-of-flash-5100-poc-nbsp-nbsp\"><span class=\"ez-toc-section\" id=\"Philips_Breaks_New_Ground_in_Point-of-Care_Ultrasound_with_Launch_of_Flash_5100_POC\"><\/span><strong>Philips Breaks New Ground in Point-of-Care Ultrasound with Launch of Flash 5100 POC&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On June 17, 2025, Royal Philips launched the Flash Ultrasound System 5100 POC, a breakthrough point-of-care ultrasound system designed for fast-paced settings like anesthesia, critical care, emergency medicine, and musculoskeletal imaging. Built on Philips\u2019 cardiology and imaging technology, the system offered high image clarity, smart automation, and a user-friendly touchscreen. Its portable design and encounter-based workflow allowed clinicians to perform and document exams in real time, supporting rapid decision-making in high-pressure environments such as the ER and ICU.<\/p>\n\n\n\n<p><em>\u201cThe Philips Flash 5100 POC represents a major leap forward in our commitment to Point-of-Care ultrasound innovation,\u201d said Jeff Cohen, Global Business Leader of Ultrasound at Philips. \u201cIt\u2019s built to empower health systems to act faster and treat smarter, delivering critical information to clinicians and non-traditional ultrasound users in the most time-sensitive and demanding environments. Designed for speed, mobility, and precision, it empowers clinicians to make confident, real-time decisions in the most urgent settings\u2014at the bedside, in the ICU, the emergency department, or the OR. With advanced algorithms and smart automation, Flash 5100 POC delivers the critical information clinicians need\u2014when and where they need it most.\u201d<\/em><\/p>\n\n\n\n<p>Philips supported around 52 million point-of-care procedures annually, aiding in the diagnosis and treatment of 41 million patients worldwide. The launch of the Flash 5100 POC marked a major advancement in meeting the demand for fast, high-performance ultrasound imaging. It featured future-ready software, cross-platform transducer compatibility, including the mL26-8 for MSK use, and integrated with Philips\u2019 POC ecosystem, including Lumify and the Compact 5000 Series. Philips also advanced innovation with two FDA-cleared AI applications for Lumify and received additional FDA clearances for the next-gen Compact 5000 Series in March, reinforcing its commitment to smarter, faster frontline care.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/point-of-care-diagnostics-market\"><strong>Point of Care Diagnostics Market Report<\/strong><\/a>, the global point of care diagnostics market is estimated to grow at a <strong>CAGR of 6.61%<\/strong> during the forecast period from 2024 to 2030. The demand for point of care diagnostics is primarily being boosted by the increasing patient population suffering from various lifestyle disorders such as diabetes and cardiovascular diseases among others, the rising prevalence of infectious diseases, growing awareness regarding health and disease-free life, and innovation in product development among others, thereby contributing to the overall growth of the point of care diagnostics market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Presidio Medical\u2122 Received IDE Approval for Ultra Low Frequency (ULF\u2122) Neuromodulation Clinical Study and Appoints Dimas Jim\u00e9nez as Chief Financial Officer&nbsp; On June 12, 2025, San Mateo, California\u2013Presidio Medical, Inc., a global clinical-stage medical device company, received Investigational New Drug (IDE) approval from the U.S. FDA to initiate its global, pivotal randomized controlled trial, the [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32512,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19511,19250,2753,17021,16975,18901,19448,22307,19422],"industry":[17226],"therapeutic_areas":[17245,17244],"class_list":["post-32510","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-endoscopes","tag-intraocular-lens","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-neuromodulation-devices","tag-point-of-care-diagnostics","tag-thrombectomy-devices","tag-tissue-heart-valves","industry-medical-devices","therapeutic_areas-neurology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Presidio Medical, Creo Medical, Penumbra<\/title>\n<meta name=\"description\" content=\"Presidio Medical\u2019s IDE Approval; Creo Medical\u2019s SpydrBlade Flex; Penumbra\u2019s STORM-PE Randomized Controlled Trial; Philips\u2019 Flash 5100 POC\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Presidio Medical, Creo Medical, Penumbra\" \/>\n<meta property=\"og:description\" content=\"Presidio Medical\u2019s IDE Approval; Creo Medical\u2019s SpydrBlade Flex; Penumbra\u2019s STORM-PE Randomized Controlled Trial; Philips\u2019 Flash 5100 POC\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-19T15:12:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-19T15:12:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/19204213\/medtech-news-for-presidio-medical-creo-medical-penumbra.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Presidio Medical, Creo Medical, Penumbra","description":"Presidio Medical\u2019s IDE Approval; Creo Medical\u2019s SpydrBlade Flex; Penumbra\u2019s STORM-PE Randomized Controlled Trial; Philips\u2019 Flash 5100 POC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Presidio Medical, Creo Medical, Penumbra","og_description":"Presidio Medical\u2019s IDE Approval; Creo Medical\u2019s SpydrBlade Flex; Penumbra\u2019s STORM-PE Randomized Controlled Trial; Philips\u2019 Flash 5100 POC","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-19T15:12:29+00:00","article_modified_time":"2025-06-19T15:12:43+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/19204213\/medtech-news-for-presidio-medical-creo-medical-penumbra.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra","name":"MedTech News | Presidio Medical, Creo Medical, Penumbra","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/19204213\/medtech-news-for-presidio-medical-creo-medical-penumbra.png","datePublished":"2025-06-19T15:12:29+00:00","dateModified":"2025-06-19T15:12:43+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Presidio Medical\u2019s IDE Approval; Creo Medical\u2019s SpydrBlade Flex; Penumbra\u2019s STORM-PE Randomized Controlled Trial; Philips\u2019 Flash 5100 POC","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-presidio-medical-creo-medical-penumbra#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/19204213\/medtech-news-for-presidio-medical-creo-medical-penumbra.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/19204213\/medtech-news-for-presidio-medical-creo-medical-penumbra.png","width":772,"height":482,"caption":"medtech-news-for-presidio-medical-creo-medical-penumbra"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/19204213\/medtech-news-for-presidio-medical-creo-medical-penumbra-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Endoscopes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">intraocular lens<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neuromodulation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Point of Care Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Thrombectomy Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tissue Heart Valves<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Endoscopes<\/span>","<span class=\"advgb-post-tax-term\">intraocular lens<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Neuromodulation Devices<\/span>","<span class=\"advgb-post-tax-term\">Point of Care Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Thrombectomy Devices<\/span>","<span class=\"advgb-post-tax-term\">Tissue Heart Valves<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 months ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Jun 19, 2025","modified":"Updated on Jun 19, 2025"},"absolute_dates_time":{"created":"Posted on Jun 19, 2025 8:42 pm","modified":"Updated on Jun 19, 2025 8:42 pm"},"featured_img_caption":"medtech-news-for-presidio-medical-creo-medical-penumbra","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32510"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32510\/revisions"}],"predecessor-version":[{"id":32513,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32510\/revisions\/32513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32512"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32510"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32510"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}